Survival Prediction on TCGA-BRCA (test)
0.81Concordance Index (CI)Cox-MT
Evaluation results
| Method | Links | ||
|---|---|---|---|
| Cox-MTModality=Single-modal, Input Type=Gene Expression2026.01 | 0.81 | — | |
| PathMoGSample Size (N)=1082, Evaluation Protocol=5-fold cross-validation2026.04 | 0.784 | 0.811 | |
| PCLSample Size (N)=1082, Evaluation Protocol=5-fold cross-validation2026.04 | 0.76 | 0.74 | |
| FGCNSample Size (N)=1082, Evaluation Protocol=5-fold cross-validation2026.04 | 0.756 | 0.69 | |
| Cox-nnetModality=Single-modal, Input Type=Gene Expression2026.01 | 0.718 | — | |
| CoxSample Size (N)=1082, Evaluation Protocol=5-fold cross-validation2026.04 | 0.712 | 0.663 | |
| ProSurvPathology Modality=true, Genomic Modality=false, Multimodal Training Unimodal Testing=true2025.03 | 0.701 | — | |
| RasaType=Bag Mix-up2025.09 | 0.6972 | — | |
| RSFSample Size (N)=1082, Evaluation Protocol=5-fold cross-validation2026.04 | 0.695 | 0.642 | |
| HDMoEGenomic Modality=true, Pathology Modality=true2026.05 | 0.686 | — | |
| PathGSample Size (N)=1082, Evaluation Protocol=5-fold cross-validation2026.04 | 0.685 | 0.776 | |
| MoMEGenomic Modality=true, Pathology Modality=true2026.05 | 0.679 | — | |
| G-HANetPathology Modality=true, Genomic Modality=true, Multimodal Training Unimodal Testing=true2025.03 | 0.677 | — | |
| SurvPathPathology Modality=true, Genomic Modality=true, Multimodal Training Unimodal Testing=false2025.03 | 0.675 | — | |
| ProSurvPathology Modality=true, Genomic Modality=true, Multimodal Training Unimodal Testing=false2025.03 | 0.675 | — | |
| MOTCatGenomic Modality=true, Pathology Modality=true2026.05 | 0.673 | — | |
| HFBSample Size (N)=1082, Evaluation Protocol=5-fold cross-validation2026.04 | 0.671 | 0.627 | |
| Shazam2025.03 | 0.67 | — | |
| CCLGenomic Modality=true, Pathology Modality=true2026.05 | 0.669 | — | |
| CAMRSample Size (N)=1082, Evaluation Protocol=5-fold cross-validation2026.04 | 0.667 | 0.717 | |
| MOTCATPathology Modality=true, Genomic Modality=true, Multimodal Training Unimodal Testing=false2025.03 | 0.665 | — | |
| LD-CVAEGenomic Modality=true, Pathology Modality=true2026.05 | 0.663 | — | |
| Phikon-v22025.03 | 0.662 | — | |
| MCATGenomic Modality=true, Pathology Modality=true2026.05 | 0.659 | — | |
| CFDLGenomic Modality=true, Pathology Modality=true2026.05 | 0.658 | — | |
| MCATPathology Modality=true, Genomic Modality=true, Multimodal Training Unimodal Testing=false2025.03 | 0.654 | — | |
| CMTAGenomic Modality=true, Pathology Modality=true2026.05 | 0.652 | — | |
| PseMixType=Bag Mix-up2025.09 | 0.65 | — | |
| SNNTransGenomic Modality=true, Pathology Modality=false2026.05 | 0.648 | — | |
| TransMILGenomic Modality=false, Pathology Modality=true2026.05 | 0.643 | — | |
| PIBDGenomic Modality=true, Pathology Modality=true2026.05 | 0.643 | — | |
| H-optimus-12025.03 | 0.64 | — | |
| GraphSSample Size (N)=1082, Evaluation Protocol=5-fold cross-validation2026.04 | 0.64 | 0.687 | |
| HEALNetFusion strategy=Hybrid early-fusion2023.11 | 0.638 | — | |
| PatchGCNType=Vision-only2025.09 | 0.6372 | — | |
| ABMILType=Vision-only2025.09 | 0.6368 | — | |
| MambaMILType=Vision-only2025.09 | 0.6366 | — | |
| SNNGenomic Modality=true, Pathology Modality=false2026.05 | 0.633 | — | |
| Prov-Gigapath2025.03 | 0.631 | — | |
| PorpoiseFusion strategy=Late2023.11 | 0.63 | — | |
| DSMILType=Vision-only2025.09 | 0.6284 | — | |
| UNI 22025.03 | 0.627 | — | |
| TransMILPathology Modality=true, Genomic Modality=false, Multimodal Training Unimodal Testing=false2025.03 | 0.625 | — | |
| Virchow22025.03 | 0.622 | — | |
| CLAM_MBGenomic Modality=false, Pathology Modality=true2026.05 | 0.62 | — | |
| MCATType=Vision & Text2025.09 | 0.6198 | — | |
| MambaMILPathology Modality=true, Genomic Modality=false, Multimodal Training Unimodal Testing=false2025.03 | 0.617 | — | |
| ABMILPathology Modality=true, Genomic Modality=false, Multimodal Training Unimodal Testing=false2025.03 | 0.613 | — | |
| WIKGPathology Modality=true, Genomic Modality=false, Multimodal Training Unimodal Testing=false2025.03 | 0.613 | — | |
| RankMixType=Bag Mix-up2025.09 | 0.612 | — | |
| MeanMILGenomic Modality=false, Pathology Modality=true2026.05 | 0.611 | — | |
| CLAM_SBGenomic Modality=false, Pathology Modality=true2026.05 | 0.609 | — | |
| MOTCATFusion strategy=Intermediate2023.11 | 0.607 | — | |
| CMTAPathology Modality=true, Genomic Modality=true, Multimodal Training Unimodal Testing=false2025.03 | 0.604 | — | |
| MaxMILGenomic Modality=false, Pathology Modality=true2026.05 | 0.6 | — | |
| TransMILType=Vision-only2025.09 | 0.5934 | — | |
| AttnMILGenomic Modality=false, Pathology Modality=true2026.05 | 0.59 | — | |
| MCATFusion strategy=Intermediate2023.11 | 0.589 | — | |
| QPMIL-VLType=Vision & Text2025.09 | 0.5826 | — | |
| MultiModNFusion strategy=Sequential Fusion2023.11 | 0.582 | — | |
| Uni-modalModality=Omics2023.11 | 0.58 | — | |
| ProSurvPathology Modality=false, Genomic Modality=true, Multimodal Training Unimodal Testing=true2025.03 | 0.578 | — | |
| SNNPathology Modality=false, Genomic Modality=true, Multimodal Training Unimodal Testing=false2025.03 | 0.576 | — | |
| PerceiverFusion strategy=Early Fusion2023.11 | 0.566 | — | |
| SNNTransPathology Modality=false, Genomic Modality=true, Multimodal Training Unimodal Testing=false2025.03 | 0.551 | — | |
| Uni-modalModality=WSI2023.11 | 0.55 | — | |
| TOPType=Vision & Text2025.09 | 0.5434 | — |